 |
|
Personalized medicine in nonalcoholic fatty liver disease
Carlos J. Pirola, Silvia Sookoian
Clin Mol Hepatol. 2022;28(4):935-938. Published online 2022 Jun 24 DOI: https://doi.org/10.3350/cmh.2022.0175
|
|
Citations to this article as recorded by
 Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
Raquel Benedé-Ubieto, Francisco Javier Cubero, Yulia A. Nevzorova
Gut Microbes.2024;[Epub] CrossRef Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice. Authors' reply
Eunice X. X. Tan, Daniel Q. Huang, Mindie H. Nguyen
Alimentary Pharmacology & Therapeutics.2024; 60(3): 411. CrossRef Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of Art Update
Silvia Sookoian, Yaron Rotman, Luca Valenti
Clinical Gastroenterology and Hepatology.2024;[Epub] CrossRef Advances in our understanding of the molecular heterogeneity of fatty liver disease: toward informed treatment decision making
Carlos J Pirola, Silvia Sookoian
Expert Review of Gastroenterology & Hepatology.2023; 17(4): 317. CrossRef Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response
Silvia Sookoian, Carlos J. Pirola
Clinical and Molecular Hepatology.2023; 29(Suppl): S184. CrossRef The effects of moderate alcohol consumption on non-alcoholic fatty liver disease
Hyunwoo Oh, Won Sohn, Yong Kyun Cho
Clinical and Molecular Hepatology.2023; 29(Suppl): S261. CrossRef
|